Epigenomics logo.png
New study published in the Journal of the National Cancer Institute concludes that Epi proColon® is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening
August 10, 2020 02:00 ET | Epigenomics AG
Under the primary base case analysis, annual mSEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and...
Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
December 02, 2019 08:30 ET | Epigenomics AG
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the...
New Micro-Simulation Study in Cancer Medicine Finds Epi proColon® Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
November 29, 2019 09:00 ET | Epigenomics AG
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the...
Epigenomics logo.png
Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon®, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates
July 24, 2019 08:30 ET | Epigenomics AG
BERLIN, July 24, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary...
Epigenomics logo.png
Epigenomics AG Receives MedTech Outlook's 2019 Top 10 In-Vitro Diagnostics Award
July 11, 2019 08:30 ET | Epigenomics AG
- Company recognized for its leadership in advancing blood-based tests to diagnose cancer - BERLIN and SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard: ECX,...
Epigenomics logo.png
New Clinical Data Support the Utility of Epi proColon® Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome
June 17, 2019 08:00 ET | Epigenomics AG
- Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the...
Epigenomics logo.png
New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon® Blood Test
May 19, 2019 12:30 ET | Epigenomics AG
– Data Presented at DDW 2019 Show 93.6% Acceptance Rate Among Patients Unwilling or Unable to Complete Other CRC Screening Tests – BERLIN and SAN DIEGO, May 19, 2019 (GLOBE NEWSWIRE) -- Epigenomics...
Sysmex and Epigenomics AG Announce Strategic R&D Collaboration in Colorectal Cancer Diagnostics
January 22, 2009 01:14 ET | Epigenomics AG
- Focus on Detection of Methylated DNA in Blood Using Sysmex Instrumentation - Sysmex Assay System to be Benchmarked Against Epigenomics' mSEPT9 Assay - Parties Entered Into...
Ad hoc: Epigenomics AG: Ad hoc Announcement According to Section 15 WpHG (German Securities Trading Act): Epigenomics AG Signs Strategic R&D Collaboration Agreement in Colorectal Cancer with Sysmex Corporation
January 22, 2009 01:11 ET | Epigenomics AG
BERLIN, Jan. 22, 2009 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (ISIN: DE000A0BVT96) today signed a strategic research and development collaboration agreement in molecular diagnostics with...
Ad hoc: Epigenomics AG: Ad hoc Announcement According to Section 15 WpHG (German Securities Trading Act): Epigenomics AG and Philips Collaborate on Integrated Automation Solutions for DNA Methylation-based Cancer Diagnostics
December 19, 2008 07:22 ET | Epigenomics AG
BERLIN, Germany, Dec. 19, 2008 (GLOBE NEWSWIRE) -- Epigenomics AG (Other OTC:EPGNF) (Frankfurt:ECX) (ISIN:DE000A0BVT96) and Royal Philips Electronics (NYSE:PHG) (AEX:PHI) today entered into a...